

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, including listings, of claims in the application.

Claim 1 (Canceled).

Claim 2 (Currently Amended): The compound according to claim ~~45~~ 46, wherein W is -NH-CH(E)- .

Claim 3 (Original): The compound according to claim 2, wherein -Z is a radical of the -Q-I-J-T type.

Claim 4 (Withdrawn): The compound according to claim 2, wherein -Z is a radical of the $\text{-(CH}_2\text{)}_s\text{-X-P-I-J-T}$ type.

Claim 5 (Withdrawn): The compound according to claim 4, wherein -X- is -O-.

Claim 6 (Withdrawn): The compound according to claim 4, wherein s is 2 and -X- is $\text{-NR}_4\text{-}$.

Claim 7 (Withdrawn): The compound of claim 45, wherein W is $\text{-N(E)-CH}_2\text{-CH}_2\text{-}$.

Claim 8 (Withdrawn): The compound according to claim 7, wherein -Z is a radical of the -Q-I-J-T type.

Claim 9 (Withdrawn): The compound according to claim 7, wherein -Z is a radical of the $\text{-(CH}_2\text{)}_s\text{-X-P-I-J-T}$ type.

Claim 10 (Withdrawn): The compound according to claim 9, wherein -X- is -O-.

Claim 11 (Withdrawn): The compound according to claim 9, wherein s is 2 and -X- is -NR⁴-.

Claim 12 (Currently Amended): The compound according to claim ~~45~~ 46, wherein -A is an -OR¹ type radical.

Claim 13 (Currently Amended): The compound according to claim ~~45~~ 46 selected from the group consisting of:

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(4-butoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-bromobenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-fluorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-*o*-tolylethoxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[3-(4-propoxyphenoxy)propoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-ethoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid methyl ester;

(2*S*)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}-3-phenylpropionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-pyridin-2-ylethoxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(pyridin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-8-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-7-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[3-(3-methylquinoxalin-2-yloxy)propoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-bromophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-fluorophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid ethyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid isopropyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid propyl ester;
(2*S*)-2-(4-benzyloxybenzoylamino)-3-(4-benzyloxyphenyl)propionic acid;
(2*S*)-2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
3-{(3-benzyloxybenzyl)-[4-(2-dibenzylaminoethoxy)benzoyl]amino}propionic acid;
3-((3-benzyloxybenzyl)-{3-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoyl}amino)propionic acid;
3-{(3-benzyloxybenzyl)-[4-(3-benzyloxybenzyloxy)benzoyl]amino}propionic acid;
2-[4-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
(2*S*)-2-[3-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
3-(4-benzyloxyphenyl)-2-[3-(biphenyl-4-ylmethoxy)benzoylamino]propionic acid;
2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-bromophenyl)propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid;
2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid;
{(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyl]amino}acetic acid;
3-{(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyl]amino}propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-bromobenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid;

3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid;
and

3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid.

Claim 14 (Currently Amended): A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to claim ~~45~~ 46 together with appropriate amounts of pharmaceutically acceptable excipients.

Claims 15-29 (Canceled).

Claim 30 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of a condition mediated by PPAR γ in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim ~~45~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 31 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of a condition mediated by both PPAR γ and PPAR δ in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim ~~45~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 32 (Withdrawn): The method according to claim 30, wherein the administration is carried out orally, parenterally or topically.

Claim 33 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a condition associated with metabolic diseases, comprising administering a therapeutically effective amount of a compound as defined in claim ~~45~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 34 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a cardiovascular disease associated with metabolic syndrome, comprising administering a therapeutically effective amount of a compound as defined in claim ~~45~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 35 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from inflammation or an inflammatory process in general, comprising administering a therapeutically effective amount of a compound as defined in claim ~~45~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 36 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from bone diseases comprising administering a therapeutically effective amount of a compound as defined in claim ~~45~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 37 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from cancer, comprising administering a therapeutically effective amount of a compound as defined in claim ~~45 together with~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 38 (Withdrawn/Currently Amended): A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids, comprising administering a therapeutically effective amount of a compound as defined in claim ~~45~~ 46 together with an appropriate amount of pharmaceutically acceptable excipients.

Claim 39 (Withdrawn): The method of claim 33, wherein the metabolic disease is non-insulin-dependent diabetes mellitus (NIDDM).

Claim 40 (Withdrawn): The method of claim 33, wherein the metabolic disease is obesity.

Claim 41 (Withdrawn): The method of claim 33, wherein the metabolic disease is selected from hypercholesterolaemia and other lipid-mediated pathologies.


Claim 42 (Withdrawn): The method of claim 35, wherein the inflammatory process is selected from rheumatoid arthritis and atherosclerosis.

Claim 43 (Withdrawn): The method of claim 35, wherein the inflammatory process is selected from psoriasis and intestinal inflammatory disease.

Claim 44 (Withdrawn): The method according to claim 31, wherein the administration is carried out orally, parenterally or topically.

Claim 45 (Canceled)

Claim 46 (New): A compound of formula (I),



(I)

its stereoisomers and mixtures thereof, and addition salts of all of them, wherein the central benzene ring may be substituted in *meta*- or *para*- position and,

-A is a radical selected from the group consisting of -OR₁, -NR₂OR₁ and -NR₂R₃; wherein R₁, R₂ and R₃ independently represent -H or -(C₁-C₄)-alkyl;

-W- is a biradical -NH-CH(E)-, wherein E is a radical of the -G-I-J-K type where:

-G-- is a bond or a -(CH₂)₁₋₄- biradical;

-I- is a biradical of a cycle selected from the following groups:

- a) cyclohexane optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkanoyl, (C₁-C₄)-alkanoyloxy, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
- b) benzene substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-J- is a bond or a biradical selected from the following groups:

- a) -(CH₂)₁₋₄-alkylidene;
- b) -O- and
- c) -O-(C₁-C₄)- alkyl-;

-K is a radical selected from the following groups:

- a) -H;
- b) (C₁-C₄)-alkyl; and

- c) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

-Z is a radical of -Q-I-J-T wherein

- Q- is a biradical $-(CH_2)_{1-3}-$;
- I- is benzene optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;
- J- is as defined above; and
- T is a radical selected from the following groups:
- a.a) -H;
- a.b) (C₁-C₄)-alkyl;
- a.c) a radical from a five- or six-membered heterocycle containing from one to two heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F; and
- a.d) phenyl or a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to two heteroatoms selected from O, S and N, the phenyl or the bicyclic system being optionally substituted by one or several radicals independently selected from -OH, -F, -Cl, -Br, (C₁-C₄)-alkyl optionally substituted by one or several -OH or -F, and (C₁-C₄)-alkoxyl optionally substituted by one or several -OH or -F;

Application Serial No. 10/560,533
Amendment dated 21 September 2009
Reply to Office Action dated 19 March 2009

with the proviso that compound of formula (I) is neither of:

2-(4-benzyloxybenzoylamino)-3-phenylpropionic acid,

2-[4-(4-methoxybenzyloxy)benzoylamino]-3-phenylpropionic acid,

2-[4-(4-bromobenzyloxy)benzoylamino]-3-phenylpropionic acid,

2-(4-benzyloxybenzoylamino)-3-biphenyl-4-ylpropionic acid or

2-(4-benzyloxybenzoylamino)-3-(4'-trifluoromethoxybiphenyl-4-yl)propionic acid.